Pharming Group N.V. has declared the successful enrollment completion in its phase 3 clinical trial of leniolisib, an investigational drug designed for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
A clinic dedicated to providing care and services to undeserved and uninsured individuals with Duchenne and Becker muscular dystrophy opened its doors on Friday (March 3).
A pediatric clinical trial expert from the CRO discusses the unique challenges involved in designing a study when the patients involved are little ones.
The virtual research organization has developed digital instruments designed for assessing stools and recording crying episodes in pediatric clinical studies.
The pharma company is evaluating its Paxlovid oral treatment, intended for high-risk patients who have tested positive for the virus, in pediatric subjects.
The AI-centered genomics company is joining with Don’t Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition.
The CRO is helping out on a project exploring the effects of the virus in children; other members of the research team include experts from Duke University.
The HIV treatment specialist has sent an application to the agency for tolutegravir, a single-tablet treatment indicated for children living with the virus.
Conducted via a partnership between Parexel and CISCRP, the study reveals insights about the needs and concerns of pediatric patients and their families.
NC-based FHI Clinical last week officially launched as a new full-service contract research organization with a global team the “right size” to adjust when needed, says CEO.
PRA Health Sciences has launched a new site network focused on improving pediatric clinical development and access to novel medicines in this special patient population.
Synteract’s clients will benefit from a single source model, says CEO, following the acquisition of KinderPharm, a PA-based CRO focused on all phases of pediatric drug development.
Ignoring pediatric considerations is no longer an option for the development of new medicines – though clinical trials in children are still not widely accepted by society, explains industry executive.
There is an increased need for transparency to improve the conduct of pediatric clinical trials and enhance the site investigator experience, says Syneos executive.
